March 11, 2020
Myovant Sciences, now a subsidiary of Sumitomo Dainippon Pharma, said on March 9 that it has filed its relugolix combination tablet (relugolix + estradiol + norethindrone) with the European Medicines Agency for the treatment of women with moderate to severe...read more